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Higher Serum Vitamin D Concentrations Are
Longitudinally Associated with Better Global Quality of
Life and Less Fatigue in Colorectal Cancer Survivors up to
2 Years after Treatment
Janna L. Koole1, Martijn J.L. Bours1, Eline H. van Roekel1, Jose J.L. Breedveld-Peters1,
Fr€anzel J.B. van Duijnhoven2, Jody van den Ouweland3, Stephanie O. Breukink4,
Maryska L.G. Janssen-Heijnen1,5, Eric T.P. Keulen6, and Matty P. Weijenberg1
ABSTRACT
◥
Background: Vitamin D status may be an important determi-
nant of health-related quality of life of colorectal cancer survivors.
The current study investigated longitudinal associations between
serum 25-hydroxyvitamin D3 (25OHD3) concentrations and qual-
ity of life in stage I–III colorectal cancer survivors up to 2 years after
treatment.
Methods: Patients with colorectal cancer (n¼ 261) were included
upon diagnosis. Home visits (including blood sampling) were per-
formed at diagnosis and at 6weeks, 6months, 1 year, and 2 years after
treatment. Serum 25OHD3 concentrations were measured using
LC/MS-MS and adjusted for season. Validated questionnaires were
used to assess global quality of life and cognitive functioning
(EORTC-QLQ-C30), fatigue (EORTC-QLQ-C30 andChecklist Indi-
vidual Strength, CIS), and depression and anxiety (Hospital Anxiety
and Depression Scale). Statistical analyses were performed using
linear mixed models and adjusted for sex, age, time since diagnosis,
therapy, comorbidities, physical activity, and body mass index.
Results: At diagnosis, 45% of patients were vitamin D
deficient (<50 nmol/L). After treatment, 25OHD3 concentra-
tions increased on average with 3.1 nmol/L every 6 months.
In confounder-adjusted models, 20 nmol/L increments in
25OHD3 were longitudinally associated with increased global
quality of life [b 2.9; 95% confidence interval (CI), 1.5–4.3] and
reduced fatigue (EORTC-QLQ-C30 subscale: b 3.5; 95% CI,
5.3 to 1.8 and CIS: b2.8; 95% CI, 4.7 to 0.9). Observed
associations were present both within and between individuals
over time.
Conclusions: Higher concentrations of 25OHD3 were longi-
tudinally associated with better global quality of life and less
fatigue in colorectal cancer survivors.
Impact: This study suggests that higher 25OHD3 con-
centrations may be beneficial for colorectal cancer survivors.
Future intervention studies are needed to corroborate these
findings.
Introduction
Colorectal cancer survivors are susceptible to enduring physical and
psychologic distress as a result of the tumor and therapy. A growing
number of individuals are living with a history of colorectal cancer
given the improving 5-year survival rate after colorectal cancer,
currently 65% in the Netherlands (1, 2). Previous studies reported
complaints of fatigue by more than one third of Dutch colorectal
cancer survivors, especially within 5 years after diagnosis (3–5).
In addition, colorectal cancer survivors are at increased risk of
impaired cognitive functioning and mental health problems such as
depression (6–8).
Vitamin D is a potentially important determinant of health-related
quality of life (HRQoL) of colorectal cancer survivors given its
involvement in many cellular processes related to cognition (9, 10),
depression (11, 12), and fatigue (13). Exposure of the skin to ultraviolet
B radiation contributes to about two thirds of vitamin D supply,
whereas about one third originates from vitamin D intake (14).
VitaminDdeficiencies have become a concern of public health (15, 16),
and the Dutch Health Council recommends women aged 50 to
70 (10 mcg) and men and women aged >70 (20 mcg) to daily
supplement vitaminD (14). No specific guidelines for cancer survivors
are available. To maintain adequate vitamin D concentrations, 15 to
30 minutes of daily sunlight exposure from March to November is
generally sufficient for the general population (17). Colorectal cancer
survivors are at risk of low vitamin D because of the negative impact
of the cancer and chemotherapy on circulating concentrations
(18–20). Moreover, the association between low vitamin D and in-
creased colorectal cancer risk (21–24) makes colorectal cancer survi-
vors particularly susceptible as low concentrations may be sustained
after therapy. Inflammation may be an important confounder in the
association between vitamin D and HRQoL. Inflammatory processes
and vitamin D interact through 1,25-dihydroxyvitamin D, the bio-
logically active metabolite also known as calcitriol, which is engaged
in different intracellular inflammatory reactions (25). In addition, as
inflammatory markers have been associated with increased fatigue
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after cancer, a potential observed association between vitamin D and
HRQoL may be altered by inflammation (26).
Few studies have investigated associations between vitamin D and
HRQoL after colorectal cancer. An observational study among 453
stage II colorectal cancer survivors reported better symptom-related
quality of life among participants using vitamin D supplements over
2 years of follow-up (27). Cancer survivors are known to be highly
motivated to intentionally alter their lifestyle in order to make health
improvements (28). Therefore, lifestyle recommendations that focus
on the enhancement of vitamin D concentrations may be an oppor-
tunity to prevent or reduce problems of diminished HRQoL after
colorectal cancer.
The objective of the present study was to investigate longitudinal
associations of serum 25-hydroxyvitamin D3 (25OHD3) concentra-
tions with HRQoL in colorectal cancer survivors from 6 weeks to
2 years after treatment, including global quality of life, fatigue,
depression, anxiety, and cognitive functioning.
Materials and Methods
Study design and population
The EnCoRe study (Energy for Life after ColoRectal Cancer) is
an ongoing prospective cohort study that was initiated in 2012
(Netherlands Trial Register no. NL6904; refs. 5, 29). The purpose of
the EnCoRe study is to evaluate longitudinal associations between
lifestyle factors and HRQoL, functioning, and prognosis after colo-
rectal cancer. Patients with stage I–III colorectal cancer ≥18 years of
age were recruited at diagnosis. Research dietitians performed home
visits at diagnosis (prior to treatment) and at 6 weeks, 6months, 1 year,
and 2 years after the end of treatment. The study was approved by the
Medical Ethics Committee of the University Hospital Maastricht and
Maastricht University, the Netherlands. All participants signed
informed consent. Exclusion criteria were: diagnosis with stage IV
colorectal cancer, no home address in the Netherlands, inability to
understand the Dutch language, and the presence of comorbidities
obstructing successful study participation. Data used in the current
analyses were based on the first 4.5 years of follow-up until November
1, 2016. Participants with at least 1 follow-up visit with available data
on both 25OHD3 and HRQoL were included in the current analyses.
The final analyses contained 261 participants at diagnosis, 260 at
6 weeks, 213 at 6 months, 168 at 12 months, and 77 at 24 months after
treatment. Response rate for inclusion was 46% and >90% for follow-
up visits.
Measurement of 25OHD3
At diagnosis, blood samples were drawn either during the first home
visit or at the hospital, and were mostly nonfasting. At follow-up,
fasting blood samples were drawn during home visits. Samples were
collected in 8.5 mL serum tubes (BD Vacutainer SST II Advance) and
pipetted into aliquots after centrifugation. Aliquots were stored at
80Cwithin 4 hours after blood draw until analysis. Serum 25OHD3
concentrations were measured using LC/MS-MS at the Canisius-
Wilhelmina Hospital in Nijmegen, the Netherlands (30). Interassay
coefficients of variation were 5.3%, 3.1%, and 2.9% at 25OHD3
concentrations of 39.0, 92.5, and 127.0 nmol/L, respectively. 25OHD3
concentrations are a robust indicator and the most commonly used
marker of vitamin D status (31).
Health-related quality of life
HRQoL was assessed during posttreatment time points. Global
quality of life, cognitive functioning, and fatigue were assessed by the
Quality of Life Questionnaire of the European Organisation for
Research and Treatment of Cancer (EORTC QLQ-C30, version 3.0;
refs. 32, 33). Higher scores reflect better global quality of life, better
cognitive functioning, and more fatigue (range, 0–100). Fatigue was
also measured by the Checklist Individual Strength (CIS), a validated
20-itemquestionnaire that has been used in colorectal cancer survivors
before (34, 35). Higher scores indicate more fatigue (range, 20–140).
Depression and anxiety were assessed using the Hospital Anxiety and
Depression Scale (HADS; refs. 36, 37). The HADS includes separate
depression and anxiety scales, and higher scores indicate more depres-
sion and anxiety (range, 0–42).
Sociodemographic, lifestyle, and clinical data
Sociodemographic information was collected based on self-report.
Cancer stage, type of therapy, and other clinical information were
obtained from medical records. Information on comorbidities at
diagnosis was retrieved frommedical records by the Charlson Comor-
bidity Index (38) and during follow-up from the Self-Administered
Comorbidity Questionnaire, which included heart condition; stroke;
high blood pressure; asthma, chronic bronchitis, or chronic obstruc-
tive pulmonary disease; diabetes; stomach ulcer; kidney disease; liver
disease; anemia or other disease of the blood; thyroid gland disease;
depression; osteoarthritis; back pain; and rheumatoid arthritis (39).
Information on dietary supplement use, including vitamin D sup-
plements, was collected during home visits. Information on (brand)
name, dosage, frequency, duration, and ingredients was listed on
standardized forms. Vitamin D intake from supplements was calcu-
lated in micrograms per day by multiplying daily frequency and
dosage. At diagnosis, participants completed a semiquantitative
253-item food frequency questionnaire to retrospectively assess die-
tary vitamin D intake during the preceding year (40). Participants
completed a 7-day dietary record as part of each posttreatment follow-
up visit. Vitamin D levels in food products for both methods were
obtained from the 2011 Dutch Food Composition Database (41).
Methods were described in more detail previously (5, 42).
Measurements of height and weight were performed during home
visits to determine body mass index (BMI). Physical activity was self-
reported using the Short QUestionnaire to ASsess Health enhancing
physical activity (SQUASH). Time spent in moderate-to-vigorous
physical activity (MVPA; ≥3 metabolic equivalents of task) was
calculated in hours/week (43). Sun exposure was self-reported at each
time point by the number of days per week that participants had spent
at least 15minutes outside (in daylight), on average over the preceding
month. The variable was dichotomized for the analyses in order to
reflect adherence to the Dutch recommendations regarding sun
exposure (spent 15 minutes outside on 7 or <7 days/week).
Plasma concentrations of inflammationmarkers IL6, IL8, IL10, and
TNFa were measured for all time points. The selection of this set of
inflammation markers was based on a review that evaluated inflam-
mation markers that interact with vitamin D and that are specifically
relevant in relation to colorectal cancer (25). Samples were collected in
6.0 mL EDTA plasma tubes (BD Vacutainer K2E) and pipetted into
aliquots after centrifugation. Aliquots were stored at 80C within
4 hours after blood draw until analysis.Measurements were performed
using a custom-made multiplex assay and electrochemiluminescence
(Meso Scale Diagnostics) atWageningen University and Research, the
Netherlands. Assay plates were analyzed on a QuickPlex SQ 120 plate
reader (Meso Scale Diagnostics).
Statistical analyses
Descriptive analyses were performed to calculate means and SD for
normally distributed variables and medians and interquartile ranges
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(IQR) for skewed variables. 25OHD3 concentrations at each time point
were adjusted for season using the week (1–52) of blood collection.
Locally weighted regression analyses (LOWESS) were performed in
order to account for the variation caused by seasonal differ-
ences (44, 45). For posttreatment time points, longitudinal associations
between 25OHD3 concentrations and HRQoL were investigated using
linear mixed-model analyses. Each model contained a random inter-
cept for subject. The addition of a random slope for vitamin D was
evaluated in each model according to the change in log-restricted
likelihood values. A separate model was used to disentangle inter- and
intraindividual associations (46). Interindividual associations were
estimated by the centered person-mean value, indicating the difference
between participants' mean 25OHD3 concentrations over time.
Intraindividual associations were estimated by the individual devia-
tions from the person-mean, indicating individual changes in vitamin
D concentration over time. Vitamin D was modeled as a conti-
nuous variable in units of 20 nmol/L and as a dichotomous variable
(vitamin D concentration <50 nmol/L; yes/no; ref. 20). In addition,
scoring on the outcomes was compared for 25OHD3 concentrations
of <30 nmol/L, 30–50 nmol/L, and >50 nmol/L. Vitamin D supple-
ment use (yes/no), total vitamin D intake from diet and supplements
(mg/day), and vitamin D intake only from supplements (mg/day) were
Table 1. Sociodemographic and clinical characteristics of study participants at time of inclusion (colorectal cancer diagnosis), included
in the EnCoRe study.
Vitamin D deficiency
(<50 nmol/L)bTotal population
(n ¼ 261)a Yes (n ¼ 111) No (n ¼ 136)
Age, mean (SD) 67 (9) 67 (9) 66 (9)
Sex, n (%)
Men 179 (69) 78 (70) 91 (67)
Women 82 (31) 33 (30) 45 (33)
Education level, n (%)
Low 66 (25) 26 (23) 35 (26)
Medium 105 (40) 48 (43) 53 (39)
High 89 (34) 37 (33) 47 (35)
Cancer type, n (%)
Colon 159 (61) 72 (65) 79 (58)
Rectum 102 (39) 39 (35) 57 (42)
Cancer stagec, n (%)
I 77 (30) 32 (30) 43 (34)
II 60 (23) 26 (24) 27 (21)
III 113 (43) 50 (46) 58 (45)
Treatment, n (%)
Neither chemotherapy nor radiotherapy 143 (55) 60 (54) 77 (57)
Chemotherapy only 46 (18) 25 (23) 18 (13)
Radiotherapy only 20 (8) 6 (5) 10 (7)
Both chemotherapy and radiotherapy 52 (20) 20 (18) 31 (23)
Inflammatory markers, median (IQR)
IL6 in pg/mL 1.1 (0.7–1.7) 1.2 (0.8–1.8) 1.0 (0.6–1.6)
IL8 in pg/mL 5.5 (4.4–8.0) 5.7 (4.4–8.0) 5.5 (4.5–7.9)
IL10 in pg/mL 0.3 (0.2–0.4) 0.3 (0.2–0.4) 0.3 (0.2–0.4)
TNFa in pg/mL 2.2 (1.8–2.8) 2.2 (1.9–2.7) 2.2 (1.7–2.8)
Summary z-score 0.1 (1.4 to 1.1) 0.1 (1.0 to 1.2) 0.1 (1.6 to 1.1)
Sun exposured, n (%)
<7 days 87 (33) 41 (37) 41 (30)
7 days 173 (67) 70 (63) 94 (70)
Number of comorbidities, n (%)
None 49 (19) 18 (16) 29 (21)
1 57 (22) 21 (19) 36 (26)
≥2 155 (59) 72 (65) 71 (52)
BMI in kg/m2, mean (SD) 28.4 (4.5) 29.2 (5.0) 27.6 (4.1)
Physical activity, median (IQR)
LPA (hours/week) 11 (4–23) 11 (4–21) 12 (4–30)
MVPA (hours/week) 11 (5–20) 11 (4–19) 12 (6–21)
Current smoking, n (%)
Yes 33 (13) 15 (14) 16 (12)
No 227 (87) 96 (86) 119 (88)
Abbreviations: BMI, body mass index; LPA, light physical activity; MVPA, moderate-to-vigorous physical activity.
aThe number of participants may slightly vary for the different variables given a small percentage of missing data.
bFourteen participants had unknown 25OHD3 status at time of inclusion.
cEleven participants had missing stage I, II, or III colorectal cancer.
dNumber of days per week spent at least 15 minutes outside (in daylight), on average over the preceding 4 weeks.
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Table 2. Descriptive statistics of 25OHD3 concentrations, vitamin D supplement use and dietary intake, HRQoL outcomes, and other
important characteristics of patients with colorectal cancer from the EnCoRe study, from inclusion (colorectal cancer diagnosis) to
24 months after treatment.
Posttreatment follow-up measurements
6 weeks 6 months 12 months 24 months
At diagnosis after treatment after treatment after treatment after treatment
n ¼ 261a n ¼ 260 n ¼ 213 n ¼ 168 n ¼ 77
25OHD3 concentration in nmol/L, median (IQR) 53.1 (40.6–67.6) 48.0 (35.2–66.1) 53.4 (41.8–69.4) 57.0 (42.5–70.5) 62.9 (46.5–82.4)
Vitamin D deficiency, n (%)
Yes (<50 nmol/L) 111 (45) 133 (53) 87 (42) 60 (36) 22 (30)
No (≥50 nmol/L) 136 (55) 120 (47) 120 (58) 106 (64) 52 (70)
Vitamin D supplement use, n (%)
Yes 62 (24) 49 (19) 44 (21) 38 (23) 17 (22)
No 194 (76) 207 (81) 163 (79) 129 (77) 60 (78)
Vitamin D intake from supplements in mg/d, median (IQR) 5 (5–10) 5 (5–10) 6 (5–15) 7 (5–20) 10 (5–20)
Dietary vitamin D intakeb in mg/d, median (IQR) 3.5 (2.5–4.7) 4.1 (2.9–5.6) 3.7 (2.8–4.7) 3.8 (2.9–5.0) 3.7 (2.6–4.6)
EORTC QLQ-C30c
Global quality of life, mean (SD) 74.1 (18.3) 76.9 (19.0) 77.8 (18.0) 79.6 (18.5)
Range (min–max) 16.7–100 0–100 0–100 33.3–100
Cognitive functioning, mean (SD) 86.3 (20.8) 85.9 (19.1) 87.6 (19.4) 87.7 (15.1)
Range (min–max) 0–100 16.7–100 16.7–100 33.3–100
Fatigue, mean (SD) 29.1 (23.0) 23.6 (21.6) 21.6 (23.0) 19.3 (21.5)
Range (min–max) 0–100 0–100 0–100 0–88.9
CIS (incl. 4 subscales)d
Total fatigue, mean (SD) 62.9 (26.4) 59.3 (27.4) 54.0 (25.9) 51.5 (25.2)
Range (min–max) 20–127 20–132 20–134 20–101
Subjective fatigue, mean (SD) 27.2 (13.3) 24.9 (12.8) 22.6 (12.3) 21.3 (12.8)
Range (min–max) 8–56 8–56 8–56 8–54
Reduced motivation, mean (SD) 12.3 (6.1) 12.0 (6.2) 10.9 (6.1) 10.5 (5.9)
Range (min–max) 4–28 4–27 4–28 4–27
Reduced physical activity, mean (SD) 10.6 (5.1) 9.6 (5.1) 8.6 (5.0) 8.1 (4.8)
Range (min–max) 3–21 3–21 3–21 3–21
Concentration problems, mean (SD) 12.9 (7.3) 12.8 (7.3) 11.9 (6.7) 11.6 (6.5)
Range (min–max) 5–34 5–33 5–31 5–28
HADS (incl. 2 subscales)e
Total depression and anxiety, mean (SD) 7.4 (6.4) 7.4 (6.7) 6.8 (6.2) 5.6 (5.5)
Range (min–max) 0–30 0–32 0–33 0–28
Depression, mean (SD) 3.8 (3.6) 3.9 (3.9) 3.4 (3.4) 2.7 (3.1)
Range (min–max) 0–15 0–19 0–17 0–14
Anxiety, mean (SD) 3.6 (3.4) 3.5 (3.4) 3.4 (3.5) 2.9 (3.1)
Range (min–max) 0–16 0–15 0–16 0–16
Inflammatory markers, median (IQR)
IL6 in pg/mL 1.1 (0.7–1.7) 1.5 (0.8–2.2) 1.2 (0.8–2.0) 0.9 (0.6–1.4) 0.9 (0.5–1.5)
IL8 in pg/mL 5.5 (4.4–8.0) 5.6 (4.4–7.3) 5.2 (4.4–7.0) 3.9 (3.1–4.8) 4.8 (3.8–6.2)
IL10 in pg/mL 0.3 (0.2–0.4) 0.4 (0.3–0.5) 0.4 (0.2–0.5) 0.2 (0.2–0.4) 0.2 (0.1–0.3)
TNFa in pg/mL 2.2 (1.8–2.8) 2.9 (2.4–3.8) 2.8 (2.3–3.6) 2.0 (1.6–2.5) 2.0 (1.6–2.9)
Summary z-score 0.1 (1.4 to 1.1) 0.1 (1.5 to 1.1) 0.2 (1.1 to 1.1) 0.3 (1.4 to 1.0) 0.1 (1.5 to 1.3)
Sun exposuref, n (%)
<7 days 87 (33) 119 (46) 87 (41) 65 (39) 32 (44)
7 days 173 (67) 141 (54) 124 (59) 102 (61) 40 (56)
Number of comorbidities, n (%)
None 49 (19) 55 (21) 49 (21) 41 (24) 16 (21)
1 57 (22) 64 (25) 51 (24) 39 (23) 17 (22)
≥2 155 (59) 141 (54) 113 (53) 87 (52) 43 (57)
BMI in kg/m2, mean (SD) 28.4 (4.5) 27.7 (4.4) 28.2 (4.4) 28.5 (4.5) 28.5 (5.0)
Physical activity, median (IQR)
LPA (hours/week) 11 (4–23) 8 (2–16) 11 (4–21) 11 (3–22) 11 (5–24)
MVPA (hours/week) 11 (5–20) 7 (3–14) 9 (4–15) 9 (4–18) 8 (3–18)
Current smoking, n (%)
Yes 33 (13) 24 (9) 17 (8) 17 (10) 6 (8)
No 227 (87) 235 (91) 194 (92) 150 (90) 66 (92)
Abbreviations: BMI, body mass index; LPA, light physical activity; MVPA, moderate-to-vigorous physical activity.
aParticipants with at least 1 follow-up measurement with available data on both vitamin D and quality of life were included in the analyses. The numbers of included
participants decrease during follow-up because data collected until November 1, 2016, were used and participants had not yet reached their follow-upmeasurement
at that time. The number of participants may slightly vary for the different variables given a small percentage of missing data.
bDietary intake of vitaminDwasmeasured by a semiquantitative 253-item food frequencyquestionnaire at diagnosis, and by a 7-daydietary record at each follow-up
measurement.
cRanges EORTC QLQ-C30 subscales: 0–100.
dRanges CIS: total score, 20–140; subjective fatigue, 8–56; reduced motivation, 4–28; reduced physical activity, 3–21; concentration problems, 5–35.
eRanges HADS: total score, 0–42; depression, 0–21; anxiety, 0–21.
fNumber of days per week spent at least 15 minutes outside (in daylight), on average over the preceding 4 weeks.
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modeled separately as the independent variable in multivariable
adjusted models to obtain more insight into the role of vitamin D
supplement use.
A summary score for the inflammatory markers was calculated by
summing z-scores of natural-log transformed concentrations of IL6,
IL8, and TNFa, and subtracting IL10, for each time point (47). Higher
scores are indicative of higher inflammation.
Relevant confounders were preselected according to the liter-
ature and included sex, age at diagnosis, time since diagnosis
(units of 6 months), cancer treatment (neither chemotherapy nor
radiotherapy, chemotherapy only, radiotherapy only, or both),
number of comorbidities (0, 1, or ≥2), MVPA (h/wk), and BMI
(kg/m2). All time-dependent variables, including confounders,
were included in the model as the repeated measurements. Other
potential covariates that did not change the beta-coefficients for
the relationship of main exposures with outcomes, and therefore
not included in the models, were: inflammatory markers (z-score),
25OHD3 at diagnosis, season, vitamin D intake from supplements
(mg/d), and sun exposure (dichotomous: spent 15 minutes outside
on 7 or <7 days/week). Subgroup analyses were performed for sex
(men/women), age at diagnosis (<70 and ≥70 years), vitamin D
supplement use (users/nonusers), and (neo-)adjuvant chemother-
apy (yes/no).
Statistical analyses were performed using Stata15 (StataCorp.).
P values <0.05 (two-sided) were considered as statistically significant.
Results
Participant characteristics
The 261 participants who enrolled in the study (31% women) had
a mean  SD age of 67  9 years (Table 1). Median 25OHD3
concentrations decreased after diagnosis and subsequently increased
during follow-up (Table 2, Fig. 1). Almost half (45%) of participants
were vitamin D deficient (<50 nmol/L) at diagnosis. Regarding the
subgroups advised to use extra vitamin D, 24% of men and women
aged ≥70 years (n ¼ 98) were vitamin D supplement users at
diagnosis. In addition, 33% of women aged 50–70 years (n ¼ 39)
used vitamin D supplements at diagnosis. Users of vitamin D
supplements had higher serum concentrations compared with non-
users (Fig. 1B). Participants who received chemotherapy had con-
sistently lower concentrations compared with the group who did not
receive chemotherapy (Fig. 1C).
Vitamin D and HRQoL
With every 6 months, global quality of life scores improved on
average by 1.3 points [95% confidence interval (CI), 0.4–2.1], and
fatigue levels decreased by 2.8 points (95% CI,3.8 to1.8; EORTC)
and 3.3 points (95% CI, 4.3 to 2.2; CIS; Table 3, Supplementary
Fig. S1).
25OHD3 was longitudinally associated with better global quality of
life (b 2.9; 95% CI, 1.5–4.3) and reduced fatigue (EORTC: b3.5; 95%
CI,5.3 to1.8 and CIS: b2.8; 95% CI,4.7 to0.9). An increase
of 20 nmol/L 25OHD3 within an individual over time was asso-
ciated with an average 3.7 point (95%CI, 1.7–5.6) higher global quality
of life score. In addition, a 20 nmol/L higher mean 25OHD3 concen-
tration between individuals over time was associated with an average
2.1 point (95%CI, 0.2–4.1) higher global quality of life score. Intra- and
interindividual associations of 25OHD3 with fatigue were of similar
degree when measured by the CIS (b's 2.5 and 3.2, respectively),
whereas for fatigue as measured by the EORTC, the association for
intraindividual changes was stronger compared with interindividual
differences (b's 4.4 and 2.6, respectively). Not being vitamin D
deficient was longitudinally associated with better global quality of
life (b 4.4; 95% CI, 1.6–7.2) and less fatigue (EORTC: b5.2; 95% CI,
8.6 to1.8 and CIS: b5.4; 95% CI,9.0 to1.8), both within and
between individuals (Table 3). Dose–response relations were observed
for the outcomes global quality of life and fatigue when comparing
the scoring of participants having severely deficient (<30 nmol/L) and
Figure 1.
Median concentrations of 25OHD3 over time from colorectal cancer diagnosis
(study inclusion) to 24 months after treatment for patients with colorectal
cancer included in the EnCoRe study, in the total population (with IQR) and
stratified by sex (A), stratified by vitamin D supplement user type (B), and
stratified by chemotherapy (C). The actual time between the measurement at
diagnosis and the measurement 6 weeks after treatment can vary between
individual patients due to differences in treatment duration.
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deficient (30–50 nmol/L) 25OHD3 concentrations, with participants
having adequate concentrations (>50 nmol/L; Fig. 2).
Although not statistically significant, better global quality of life and
less fatigue (EORTC QLQ-C30) were observed for individuals who
changed from being nonuser to user of vitamin D supplements over
time, whereas interindividual differences suggested lower global qual-
ity of life and more fatigue for supplement users compared with
nonusers (Table 4). No longitudinal associations were found between
the sum of dietary and supplemental vitamin D intake with global
quality of life and fatigue, and between vitamin D intake from
supplements only and these outcomes.
In subgroup analyses, longitudinal associations of 25OHD3 con-
centrations with global quality of life and fatigue were only present in
men (Supplementary Table S1).
Discussion
To our knowledge, the current study is the first to investigate
longitudinal associations between serum 25OHD3 concentrations and
HRQoL outcomes in colorectal cancer survivors. Higher concentra-
tions of 25OHD3 were longitudinally associated with better global
quality of life and less fatigue from6weeks up to 2 years after colorectal
cancer treatment, both within and between individuals. In addition,
having a vitamin D deficiency was associated with lower global quality
of life and more fatigue. Intraindividual associations suggested better
global quality of life and less fatigue for individuals who started using
vitamin D supplements during follow-up.
The prevalence of vitamin D deficiency increased from 45% at
diagnosis to 53% 6 weeks after treatment (cutoff 50 nmol/L). The
latter is slightly higher compared with the general Dutch population
aged 60þ with prevalences of 34% to 51% (48). A study among
2,910 patients with stage I–IV colorectal cancer from Germany
observed deficiencies in 84% of participants, yet samples were
assessed approximately 3 weeks after diagnosis (49). Another study
among 1,598 Scottish patients with stage I–III colorectal cancer
found concentrations <25 nmol/L among 50% of participants
approximately 15 weeks after treatment (50). This compares with
only 10% of participants when using the cutoff point of 25 nmol/L
in our population. Differences may be due to vitamin D supplement
use, latitude, and time of sampling as concentrations in our study
steadily increased after treatment. Nevertheless, the important
health concern of vitamin D deficiency among this group of patients
is indisputable.
Previous studies examining the potential relation between vitamin
D and aspects of HRQoL are still inconclusive and scarce among
population subgroups such as cancer survivors. A systematic literature
review concluded a moderate positive effect of short-term vitamin D
supplementation on HRQoL in clinical populations, not including
cancer survivors (51). Despite the large heterogeneity between studies
included in this review, results correspond to the observed associations
Figure 2.
Comparison of scoring on quality of life outcomes over time for participants having severely deficient (<30 nmol/L) and deficient (30–50 nmol/L) 25OHD3
concentrations, with participants having adequate concentrations (>50 nmol/L), from 6 weeks to 24months after treatment in patients with colorectal cancer from
the EnCoRe study.
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of the current study. Regarding fatigue, contradicting results were
found in two intervention studies. A randomized placebo-controlled
trial among patients with chronic fatigue syndrome found no effect of
vitamin D supplementation (52), whereas another trial for treating
fatigue among otherwise healthy individuals observed lower fatigue
among vitamin D supplement users compared with a placebo
group (53). A retrospective study among 100 ambulatory advanced
cancer patients, including patients with gastrointestinal cancer, found
no association between vitamin D concentrations and symptoms of
depression, anxiety, and fatigue (54). Our study neither found associa-
tions between serum 25OHD3 concentrations and depression, anxiety,
and cognitive functioning, potentially caused by the lack of variation
over time in these outcomes. In summary, results from the current
study are largely in line with the literature, yet comparing results is
difficult given the large differences in methodology and study para-
meters between studies.
The observed effect sizes for associations with global quality of life
and fatigue were small and could raise questions about clinical
relevance. Minimally important differences for global quality of
life and fatigue (EORTC QLQ-C30) were defined as 10 and 9
points (55, 56), respectively, and for overall fatigue (CIS) as 10
points (57). Increments of 20 nmol/L 25OHD3 were used as
clinically relevant contrast as it resembled 1 SD and represented
realistic fluctuations in intraindividual 25OHD3 concentrations.
Although effect sizes were larger in dichotomous analyses (vitamin
D deficiency yes/no), none of the effect sizes reached the level of
clinical relevance. Nevertheless, observed beta-coefficients suggest
the presence of a longitudinal association between higher 25OHD3
and better HRQoL.
An important strength of the current study was the prospective
character with repeated measurements of 25OHD3 and HRQoL out-
comes. Further, follow-up response rateswere high, and the percentage
of missing data was low. Another strength was the use of mixed-model
analysis techniques that enabled disentangling of inter- and intrain-
dividual associations, thereby providing additional insights into the
nature of the associations. A limitation of the current study concerns
the inability to draw conclusions on causality. Observed associations
could be due to the fact that colorectal cancer survivors with poorer
HRQoL spend more time indoors, resulting in lower 25OHD3 con-
centrations. However, adjustment for sun exposure did not change the
associations. In addition, despite adjustment for important variables
such as therapy, residual confounding may have occurred, as observed
associations could be caused by unmeasured underlying factors related
to the cancer that also influenced biological mechanisms related to
25OHD3 and HRQoL.
The use of vitamin D supplements was low despite the national
recommendations that applied to about half of the study popula-
tion. Although vitamin D supplement users on average had higher
serum 25OHD3 concentrations compared with nonusers, no direct
beneficial association of vitamin D supplement use with HRQoL
was found. In addition, associations of 25OHD3 with global quality
of life and fatigue were also present in participants not using
vitamin D supplements. In fact, vitamin D supplement use itself
seemed associated with poorer HRQoL and more fatigue in inter-
individual associations. An alternative explanation, also hypothe-
sized by Patterson and colleagues (58), is that supplement use may
be a coping strategy rather than actually improving health of cancer
survivors. Associations with supplement use should therefore be
interpreted with caution, because individuals with poorer HRQoL
and more fatigue may begin to use (vitamin D) supplements as a
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contrarily suggested that individuals who started using supplements
during follow-up were generally likely to report better global quality
of life and less fatigue. Whether this association is causal needs to be
addressed in intervention studies.
Our study does not provide strong enough evidence to formulate
recommendations on the necessity of vitamin D supplementation
for colorectal cancer survivors. However, higher 25OHD3 concen-
trations seem beneficial, and colorectal cancer survivors are advised
to follow the guidelines for the general Dutch population because no
specific guidelines on vitamin D for cancer survivors are available.
According to the national guidelines, women aged >50 and women
and men aged >70 are recommended to use vitamin D supplements
(10 and 20 mcg, respectively) to ensure adequate blood concentra-
tions for the prevention of osteoporosis (14). In addition, all
colorectal cancer survivors should spend the recommended time
outdoors to sufficiently expose their skin to sunlight (17). In
practice, however, many colorectal cancer survivors seem unaware
of the prevailing recommendations, potentially as a consequence of
the lack of proper information provided.
In conclusion, our results suggest that higher 25OHD3 con-
centrations are longitudinally associated with better global quality
of life and reduced fatigue in colorectal cancer survivors. It is
important for colorectal cancer survivors to become aware of the
national guidelines regarding sun exposure and vitamin D sup-
plementation, and individual 25OHD3 status should be moni-
tored by medical professionals. Placebo-controlled randomized
trials are needed to examine the potential advantage of the use of
vitamin D supplements in colorectal cancer survivors for
improvement of HRQoL and fatigue to clarify questions on cause
and effect and to deepen the understanding of possible underlying
mechanisms.
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